Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia

Heart Lung and Circulation

Volumn 25, Issue 8, 2016, Pages 777-783

  Imberti, Jacopo F ^a   Underwood, Katherine ^a   Mazzanti, Andrea ^a   Priori, Silvia G ^a,b  

^a IRCCS   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Beta blocker; Bidirectional ventricular tachycardia; CASQ2; Catecholaminergic polymorphic ventricular tachycardia; Exercise induced cardiac arrest; Exercise induced syncope; Flecainide; Implantable cardioverter defibrillator; RyR2; Sudden cardiac death

Indexed keywords

FLECAINIDE; NADOLOL; PROPRANOLOL;

CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CLINICAL FEATURE; DRUG EFFICACY; ELECTROCARDIOGRAPHY; GENETIC BACKGROUND; GENETIC SCREENING; HEART DENERVATION; HEART FUNCTION TEST; HUMAN; INCIDENCE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; FEMALE; MALE; PATHOPHYSIOLOGY; PROCEDURES; SYMPATHECTOMY; TACHYCARDIA, VENTRICULAR;

FEMALE; FLECAINIDE; HUMANS; MALE; PREVALENCE; SYMPATHECTOMY; TACHYCARDIA, VENTRICULAR;

EID: 84959267575     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2016.01.012     Document Type: Review

References (48)

1. [1] Coumel, P., Catecholamine-induced severe ventricular arrhythmias with Adams-Stokes syndrome in children: a report of four cases. Br Heart J. 40 (1978), 28–37.
2. [2] Tester, D.J., Medeiros-Domingo, A., Will, M.L., Haglund, C.M., Ackerman, M.J., Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing. Mayo Clin Proc. 87 (2012), 524–539.
3. [3] Priori, S.G., Blomstrom-Lundqvist, C., Mazzanti, A., Blom, N., Borggrefe, M., Camm, J.A., et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 36 (2015), 2793–2867.
4. [4] Priori, S.G., Wilde, A.A., Horie, M., Cho, Y., Behr, E.R., Berul, C., et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace. 15 (2013), 1389–1406.
5. [5] Leenhardt, A., Lucet, V., Denjoy, I., Grau, F., Ngoc, D.D., Coumel, P., Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation. 91 (1995), 1512–1519.
6. [6] Priori, S.G., Napolitano, C., Memmi, M., Colombi, B., Drago, F., Gasparini, M., et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 106 (2002), 69–74.
7. [7] Roston, T.M., Vinocur, J.M., Maginot, K.R., Mohammed, S., Salerno, J.C., Etheridge, S.P., et al. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry. Circ Arrhythm Electrophysiol. 8 (2015), 633–642.
8. [8] Ackerman, M.J., Priori, S.G., Willems, S., Berul, C., Brugada, R., Calkins, H., et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Europace. 13 (2011), 1077–1109.
9. [9] Jimenez-Jaimez, J., Peinado, R., Grima, E.Z., Segura, F., Morina, P., Sanchez Munoz, J.J., et al. Diagnostic Approach to Unexplained Cardiac Arrest (from the FIVI-Gen Study). Am J Cardiol. 116 (2015), 894–899.
10. [10] Ackerman, M.J., Priori, S.G., Willems, S., Berul, C., Brugada, R., Calkins, H., et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm. 8 (2011), 1308–1339.
11. [11] Fabiato, A., Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol. 245 (1983), C1–C14.
12. [12] Lahat, H., Pras, E., Olender, T., Avidan, N., Ben-Asher, E., Man, O., et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet. 69 (2001), 1378–1384.
13. [13] Gaburjakova, M., Bal, N.C., Gaburjakova, J., Periasamy, M., Functional interaction between calsequestrin and ryanodine receptor in the heart. Cell Mol Life Sci. 70 (2013), 2935–2945.
14. [14] Bers, D.M., Sarcoplasmic reticulum Ca release in intact ventricular myocytes. Front Biosci. 7 (2002), d1697–d1711.
15. [15] Priori, S.G., Napolitano, C., Intracellular calcium handling dysfunction and arrhythmogenesis: a new challenge for the electrophysiologist. Circ Res. 97 (2005), 1077–1079.
16. [16] Roux-Buisson, N., Cacheux, M., Fourest-Lieuvin, A., Fauconnier, J., Brocard, J., Denjoy, I., et al. Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human. Hum Mol Genet. 21 (2012), 2759–2767.
17. [17] Rooryck, C., Kyndt, F., Bozon, D., Roux-Buisson, N., Sacher, F., Probst, V., et al. New Family With Catecholaminergic Polymorphic Ventricular Tachycardia Linked to the Triadin Gene. J Cardiovasc Electrophysiol. 26 (2015), 1146–1150.
18. [18] Nyegaard, M., Overgaard, M.T., Sondergaard, M.T., Vranas, M., Behr, E.R., Hildebrandt, L.L., et al. Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death. Am J Hum Genet. 91 (2012), 703–712.
19. [19] Mohler, P.J., Splawski, I., Napolitano, C., Bottelli, G., Sharpe, L., Timothy, K., et al. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proc Natl Acad Sci U S A. 101 (2004), 9137–9142.
20. [20] Plaster, N.M., Tawil, R., Tristani-Firouzi, M., Canun, S., Bendahhou, S., Tsunoda, A., et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell. 105 (2001), 511–519.
21. [21] di Barletta, M.R., Viatchenko-Karpinski, S., Nori, A., Memmi, M., Terentyev, D., Turcato, F., et al. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation. 114 (2006), 1012–1019.
22. [22] Postma, A.V., Denjoy, I., Hoorntje, T.M., Lupoglazoff, J.M., Da Costa, A., Sebillon, P., et al. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res. 91 (2002), e21–e26.
23. [23] Sumitomo, N., Harada, K., Nagashima, M., Yasuda, T., Nakamura, Y., Aragaki, Y., et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart. 89 (2003), 66–70.
24. [24] Postma, A.V., Denjoy, I., Kamblock, J., Alders, M., Lupoglazoff, J.M., Vaksmann, G., et al. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet. 42 (2005), 863–870.
25. [25] Rosen, M.R., Danilo, P. Jr., Effects of tetrodotoxin, lidocaine, verapamil, and AHR-2666 on Ouabain-induced delayed afterdepolarizations in canine Purkinje fibers. Cir Res. 46 (1980), 117–124.
26. [26] Priori, S.G., Napolitano, C., Tiso, N., Memmi, M., Vignati, G., Bloise, R., et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 103 (2001), 196–200.
27. [27] Cerrone, M., Colombi, B., Santoro, M., di Barletta, M.R., Scelsi, M., Villani, L., et al. Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. Circ Res. 96 (2005), e77–e82.
28. [28] Cerrone, M., Noujaim, S.F., Tolkacheva, E.G., Talkachou, A., O'Connell, R., Berenfeld, O., et al. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circ Res. 101 (2007), 1039–1048.
29. [29] Herron, T.J., Milstein, M.L., Anumonwo, J., Priori, S.G., Jalife, J., Purkinje cell calcium dysregulation is the cellular mechanism that underlies catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 7 (2010), 1122–1128.
30. [30] Neco, P., Torrente, A.G., Mesirca, P., Zorio, E., Liu, N., Priori, S.G., et al. Paradoxical effect of increased diastolic Ca(2+) release and decreased sinoatrial node activity in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circulation. 126 (2012), 392–401.
31. [31] Aizawa, Y., Komura, S., Okada, S., Chinushi, M., Aizawa, Y., Morita, H., et al. Distinct U wave changes in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT). Int Heart J. 47 (2006), 381–389.
32. [32] Marjamaa, A., Hiippala, A., Arrhenius, B., Lahtinen, A.M., Kontula, K., Toivonen, L., et al. Intravenous epinephrine infusion test in diagnosis of catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Electrophysiol. 23 (2012), 194–199.
33. [33] van der Werf, C., Nederend, I., Hofman, N., van Geloven, N., Ebink, C., Frohn-Mulder, I.M., et al. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives. Circ Arrhythm Electrophysiol. 5 (2012), 748–756.
34. [34] Hayashi, M., Denjoy, I., Extramiana, F., Maltret, A., Buisson, N.R., Lupoglazoff, J.M., et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 119 (2009), 2426–2434.
35. [35] Leren, I.S., Saberniak, J., Majid, E., Haland, T.F., Edvardsen, T., Haugaa, K.H., Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with beta-selective beta-blockers in patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm., 2015 Sep 30 pii: S1547-5271(15)01237-0.
36. [36] Hayashi, M., Denjoy, I., Hayashi, M., Extramiana, F., Maltret, A., Roux-Buisson, N., et al. The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands. Europace. 14 (2012), 1344–1351.
37. [37] Kurtzwald-Josefson, E., Hochhauser, E., Bogachenko, K., Harun-Khun, S., Katz, G., Aravot, D., et al. Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice. Heart Rhythm. 11 (2014), 1471–1479.
38. [38] Watanabe, H., Chopra, N., Laver, D., Hwang, H.S., Davies, S.S., Roach, D.E., et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 15 (2009), 380–383.
39. [39] van der Werf, C., Kannankeril, P.J., Sacher, F., Krahn, A.D., Viskin, S., Leenhardt, A., et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 57 (2011), 2244–2254.
40. [40] Padfield, G.J., Al Ahmari, L., Lieve, K.V., AlAhmari, T., Roston, T.M., Wilde, A.A., et al. Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of beta-blockade. Heart Rhythm.(Sep 28), 2015 pii: S1547-5271(15)01197-2.
41. [41] Napolitano, C., Flecainide monotherapy for catecholaminergic polymorphic ventricular tachycardia: Perspectives and limitations. Heart Rhythm.(Oct 21), 2015 pii: S1547-5271(15)01313-2.
42. [42] Moss, A.J., McDonald, J., Unilateral cervicothoracic sympathetic ganglionectomy for the treatment of long QT interval syndrome. N Engl J Med. 285 (1971), 903–904.
43. [43] Schneider, H.E., Steinmetz, M., Krause, U., Kriebel, T., Ruschewski, W., Paul, T., Left cardiac sympathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome. Clin Res Cardiol. 102 (2013), 33–42.
44. [44] Coleman, M.A., Bos, J.M., Johnson, J.N., Owen, H.J., Deschamps, C., Moir, C., et al. Videoscopic left cardiac sympathetic denervation for patients with recurrent ventricular fibrillation/malignant ventricular arrhythmia syndromes besides congenital long-QT syndrome. Circ Arrhythm Electrophysiol. 5 (2012), 782–788.
45. [45] De Ferrari, G.M., Dusi, V., Spazzolini, C., Bos, J.M., Abrams, D.J., Berul, C.I., et al. Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation. Circulation. 131 (2015), 2185–2193.
46. [46] Odero, A., Bozzani, A., De Ferrari, G.M., Schwartz, P.J., Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias: the surgical supraclavicular approach to cervicothoracic sympathectomy. Heart Rhythm. 7 (2010), 1161–1165.
47. [47] Denegri, M., Bongianino, R., Lodola, F., Boncompagni, S., De Giusti, V.C., Avelino-Cruz, J.E., et al. Single delivery of an adeno-associated viral construct to transfer the CASQ2 gene to knock-in mice affected by catecholaminergic polymorphic ventricular tachycardia is able to cure the disease from birth to advanced age. Circulation. 129 (2014), 2673–2681.
48. [48] Liu, N., Denegri, M., Dun, W., Boncompagni, S., Lodola, F., Protasi, F., et al. Abnormal propagation of calcium waves and ultrastructural remodeling in recessive catecholaminergic polymorphic ventricular tachycardia. Circ Res. 113 (2013), 142–152.